These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32267185)

  • 1. Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis.
    Athavale A; Jamshidi N; Roberts DM
    Clin Toxicol (Phila); 2020 Aug; 58(8):789-800. PubMed ID: 32267185
    [No Abstract]   [Full Text] [Related]  

  • 2. Whole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran.
    Takeshita S; Tanaka KA; Sawa T; Sanda M; Mizobe T; Ogawa S
    Anesth Analg; 2020 Feb; 130(2):535-541. PubMed ID: 31490820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
    Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
    Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
    Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
    J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
    Glund S; Coble K; Gansser D; Stangier J; Hoermann K; Pollack CV; Reilly P
    J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
    Glund S; Stangier J; van Ryn J; Schmohl M; Moschetti V; Haazen W; De Smet M; Gansser D; Norris S; Lang B; Reilly P; Kreuzer J
    Clin Pharmacokinet; 2017 Jan; 56(1):41-54. PubMed ID: 27317414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refractory Dabigatran-Induced Hemorrhage Despite Multiple Idarucizumab Administration and Renal Replacement Therapy.
    Flynn F; Richard G; Dobrescu MA; Bouchard J; Williamson D; Brindamour D; Charbonney E; Dupuis S
    J Pharm Pract; 2022 Apr; 35(2):302-307. PubMed ID: 32985337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Goal-directed administration of antidote for reversal of dabigatran anticoagulation].
    Lindeman E
    Lakartidningen; 2017 Dec; 114():. PubMed ID: 29292966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study.
    Yasaka M; Ikushima I; Harada A; Imazu S; Taniguchi A; Norris S; Gansser D; Stangier J; Schmohl M; Reilly PA
    Res Pract Thromb Haemost; 2017 Oct; 1(2):202-215. PubMed ID: 30046691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
    Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of Dabigatran Using Idarucizumab in a Septic Patient with Impaired Kidney Function in Real-Life Practice.
    Sauter TC; Blum S; Nagler M; Schlittler FL; Ricklin ME; Exadaktylos AK
    Case Rep Emerg Med; 2016; 2016():1393057. PubMed ID: 27547476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study.
    Wang Z; Zhao X; He P; Chen S; Jiang J; Harada A; Brooks S; Cui Y
    Adv Ther; 2020 Sep; 37(9):3916-3928. PubMed ID: 32691242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
    Ströhle M; Rugg C; Schmid S; Fries D; Oswald E
    Trauma Case Rep; 2021 Apr; 32():100422. PubMed ID: 33665315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran.
    Brennan Y; Favaloro EJ; Pasalic L; Keenan H; Curnow J
    Intern Med J; 2019 Jan; 49(1):59-65. PubMed ID: 29869387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting.
    Gendron N; Chocron R; Billoir P; Brunier J; Camoin-Jau L; Tuffigo M; Faille D; Teissandier D; Gay J; de Raucourt E; Suner L; Bonnet C; Martin AC; Lasne D; Ladhari C; Lebreton A; Bertoletti L; Ajzenberg N; Gaussem P; Morange PE; Le Cam Duchez V; Viallon A; Roy PM; Lillo-le Louët A; Smadja DM
    Front Med (Lausanne); 2020; 7():599626. PubMed ID: 33392223
    [No Abstract]   [Full Text] [Related]  

  • 18. Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study.
    Yasaka M; Yokota H; Suzuki M; Asakura H; Yamane T; Ogi Y; Kimoto T; Nakayama D
    Cardiol Ther; 2023 Dec; 12(4):723-740. PubMed ID: 37845427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination.
    Glund S; Gan G; Moschetti V; Reilly P; Honickel M; Grottke O; Van Ryn J
    Clin Appl Thromb Hemost; 2018 Jul; 24(5):724-733. PubMed ID: 29534609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Analysis of the Effectiveness of a Reduced Dose of Idarucizumab in Dabigatran Reversal.
    Stone L; Merriman E; Hanna M; Royle G; Chan H
    Thromb Haemost; 2022 Jul; 122(7):1096-1103. PubMed ID: 34814227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.